• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在计算机上鉴定严重急性呼吸综合征冠状病毒2型主要蛋白酶(M)的潜在抑制剂

In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (M).

作者信息

Hernández-Serda Manuel Alejandro, Vázquez-Valadez Víctor H, Aguirre-Vidal Pablo, Markarian Nathan M, Medina-Franco José L, Cardenas-Granados Luis Alfonso, Alarcón-López Aldo Yoshio, Martínez-Soriano Pablo A, Velázquez-Sánchez Ana María, Falfán-Valencia Rodolfo E, Angeles Enrique, Abrahamyan Levon

机构信息

Departamento de Ciencias Químicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.

Departamento de Ciencias Biológicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.

出版信息

Pathogens. 2024 Oct 11;13(10):887. doi: 10.3390/pathogens13100887.

DOI:10.3390/pathogens13100887
PMID:39452758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11510711/
Abstract

The ongoing Coronavirus Disease 19 (COVID-19) pandemic has had a profound impact on the global healthcare system. As the SARS-CoV-2 virus, responsible for this pandemic, continues to spread and develop mutations in its genetic material, new variants of interest (VOIs) and variants of concern (VOCs) are emerging. These outbreaks lead to a decrease in the efficacy of existing treatments such as vaccines or drugs, highlighting the urgency of new therapies for COVID-19. Therefore, in this study, we aimed to identify potential SARS-CoV-2 antivirals using a virtual screening protocol and molecular dynamics simulations. These techniques allowed us to predict the binding affinity of a database of compounds with the virus M protein. This in silico approach enabled us to identify twenty-two chemical structures from a public database (QSAR Toolbox Ver 4.5 ) and ten promising molecules from our in-house database. The latter molecules possess advantageous qualities, such as two-step synthesis, cost-effectiveness, and long-lasting physical and chemical stability. Consequently, these molecules can be considered as promising alternatives to combat emerging SARS-CoV-2 variants.

摘要

持续的新型冠状病毒肺炎(COVID-19)大流行对全球医疗系统产生了深远影响。随着导致此次大流行的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒继续传播并在其遗传物质中发生突变,新的关注变异株(VOIs)和关切变异株(VOCs)不断出现。这些疫情导致疫苗或药物等现有治疗方法的疗效下降,凸显了针对COVID-19的新疗法的紧迫性。因此,在本研究中,我们旨在使用虚拟筛选方案和分子动力学模拟来鉴定潜在的SARS-CoV-2抗病毒药物。这些技术使我们能够预测化合物数据库与病毒M蛋白的结合亲和力。这种计算机模拟方法使我们能够从公共数据库(QSAR Toolbox Ver 4.5)中识别出22种化学结构,并从我们的内部数据库中识别出10种有前景的分子。后一类分子具有诸如两步合成、成本效益以及持久的物理和化学稳定性等优势特性。因此,这些分子可被视为对抗新出现的SARS-CoV-2变异株的有前景的替代物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/d6ef6f275019/pathogens-13-00887-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/ce1f9cced20e/pathogens-13-00887-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/2766177b69aa/pathogens-13-00887-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/d3f98d733e70/pathogens-13-00887-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/2d0e6d9bf7f0/pathogens-13-00887-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/d96f7d584ded/pathogens-13-00887-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/9d32a0c1360e/pathogens-13-00887-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/c2df00ff68bb/pathogens-13-00887-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/b06d779d5827/pathogens-13-00887-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/73ce65ac3dce/pathogens-13-00887-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/4ebeb07c7eb0/pathogens-13-00887-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/5cb8b153844c/pathogens-13-00887-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/681637712f10/pathogens-13-00887-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/d6ef6f275019/pathogens-13-00887-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/ce1f9cced20e/pathogens-13-00887-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/2766177b69aa/pathogens-13-00887-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/d3f98d733e70/pathogens-13-00887-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/2d0e6d9bf7f0/pathogens-13-00887-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/d96f7d584ded/pathogens-13-00887-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/9d32a0c1360e/pathogens-13-00887-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/c2df00ff68bb/pathogens-13-00887-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/b06d779d5827/pathogens-13-00887-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/73ce65ac3dce/pathogens-13-00887-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/4ebeb07c7eb0/pathogens-13-00887-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/5cb8b153844c/pathogens-13-00887-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/681637712f10/pathogens-13-00887-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6f2/11510711/d6ef6f275019/pathogens-13-00887-g013.jpg

相似文献

1
In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (M).在计算机上鉴定严重急性呼吸综合征冠状病毒2型主要蛋白酶(M)的潜在抑制剂
Pathogens. 2024 Oct 11;13(10):887. doi: 10.3390/pathogens13100887.
2
Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase approach.将美国食品药品监督管理局(FDA)批准的药物用于治疗新型冠状病毒肺炎(COVID-19):通过多阶段方法靶向主要蛋白酶。
Antivir Ther. 2024 Dec;29(6):13596535241305536. doi: 10.1177/13596535241305536.
3
identification of D449-0032 compound as a putative SARS-CoV-2 M inhibitor.鉴定 D449-0032 化合物为潜在的 SARS-CoV-2 M 抑制剂。
J Biomol Struct Dyn. 2024 Aug;42(12):6440-6447. doi: 10.1080/07391102.2023.2234045. Epub 2023 Jul 9.
4
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.靶向 SARS-CoV-2 主蛋白酶:一项计算药物再利用研究。
Arch Med Res. 2021 Jan;52(1):38-47. doi: 10.1016/j.arcmed.2020.09.013. Epub 2020 Sep 17.
5
Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M) of SARS-CoV-2.维甲酰萘醌 A 片段衍生物作为抗严重急性呼吸综合征冠状病毒 2 主蛋白酶 (M) 的潜在治疗先导物的构效关系 (SAR) 和分子动力学研究。
J Mol Model. 2021 Feb 28;27(3):97. doi: 10.1007/s00894-021-04703-6.
6
In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease.基于有机三唑的配体作为严重急性呼吸综合征冠状病毒2主蛋白酶潜在抑制性药物化合物的计算机模拟鉴定与验证
Molecules. 2021 Oct 14;26(20):6199. doi: 10.3390/molecules26206199.
7
Identification of promising SARS-CoV-2 main protease inhibitor through molecular docking, dynamics simulation, and ADMET analysis.通过分子对接、动力学模拟和ADMET分析鉴定有前景的新型冠状病毒主要蛋白酶抑制剂。
Sci Rep. 2025 Jan 22;15(1):2830. doi: 10.1038/s41598-025-86016-9.
8
Analysis of bioactive compounds of as potential inhibitors of SARS-CoV-2 main protease: a pharmacokinetics, molecular docking and molecular dynamics simulation studies.作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶潜在抑制剂的生物活性化合物分析:药代动力学、分子对接和分子动力学模拟研究
J Biomol Struct Dyn. 2025 Feb;43(3):1147-1158. doi: 10.1080/07391102.2023.2291172. Epub 2023 Dec 8.
9
Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.通过基于结构的虚拟筛选方法合成和鉴定新型抗 COVID-19 主蛋白酶的潜在分子。
Appl Biochem Biotechnol. 2021 Nov;193(11):3602-3623. doi: 10.1007/s12010-021-03615-8. Epub 2021 Jul 29.
10
Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Protease.利用定量构效关系、对接和分子动力学对严重急性呼吸综合征冠状病毒2 M蛋白酶的潜在抑制剂进行药物再利用研究
Molecules. 2020 Nov 6;25(21):5172. doi: 10.3390/molecules25215172.

本文引用的文献

1
In silico guided screening of active components of as 3-chymotrypsin-like protease inhibitors of novel coronavirus.基于计算机模拟的新型冠状病毒3-糜蛋白酶样蛋白酶抑制剂活性成分筛选
3 Biotech. 2023 Oct;13(10):324. doi: 10.1007/s13205-023-03745-2. Epub 2023 Aug 31.
2
Computational investigation of natural compounds as potential main protease (M) inhibitors for SARS-CoV-2 virus.计算研究天然化合物作为 SARS-CoV-2 病毒主要蛋白酶(M)抑制剂的潜力。
Comput Biol Med. 2022 Dec;151(Pt A):106318. doi: 10.1016/j.compbiomed.2022.106318. Epub 2022 Nov 18.
3
Computational assessment of herbal medicine-derived compounds as potential inhibitors of SARS-CoV-2 main protease.
计算评估草药衍生化合物作为 SARS-CoV-2 主蛋白酶潜在抑制剂的研究。
J Biomol Struct Dyn. 2023 Nov;41(19):9602-9613. doi: 10.1080/07391102.2022.2144949. Epub 2022 Nov 14.
4
Evasion of neutralising antibodies by omicron sublineage BA.2.75.奥密克戎亚谱系BA.2.75对中和抗体的逃逸
Lancet Infect Dis. 2022 Oct;22(10):1421-1422. doi: 10.1016/S1473-3099(22)00524-2. Epub 2022 Sep 1.
5
The SARS-CoV-2 main protease (M): Structure, function, and emerging therapies for COVID-19.严重急性呼吸综合征冠状病毒2型主要蛋白酶(M):结构、功能及针对2019冠状病毒病的新兴疗法
MedComm (2020). 2022 Jul 14;3(3):e151. doi: 10.1002/mco2.151. eCollection 2022 Sep.
6
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.SARS-CoV-2 奥密克戎亚变种 BA.2.12.1、BA.4 和 BA.5 的抗体逃逸
Nature. 2022 Aug;608(7923):603-608. doi: 10.1038/s41586-022-05053-w. Epub 2022 Jul 5.
7
Inhibition of the main protease of SARS-CoV-2 (M) by repurposing/designing drug-like substances and utilizing nature's toolbox of bioactive compounds.通过重新利用/设计类药物物质并利用生物活性化合物的天然宝库来抑制新型冠状病毒肺炎(SARS-CoV-2)的主要蛋白酶(M)
Comput Struct Biotechnol J. 2022;20:1306-1344. doi: 10.1016/j.csbj.2022.03.009. Epub 2022 Mar 14.
8
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.免疫功能低下患者持续性 SARS-CoV-2 感染治疗过程中雷米昔韦耐药突变的从头出现:一例病例报告。
Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y.
9
Basic virology of SARS-CoV 2.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的基础病毒学
Indian J Med Microbiol. 2022 Apr-Jun;40(2):182-186. doi: 10.1016/j.ijmmb.2022.02.005. Epub 2022 Mar 14.
10
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.SARS-CoV-2 变体的主要蛋白酶突变体仍然对奈玛特韦敏感。
Bioorg Med Chem Lett. 2022 Apr 15;62:128629. doi: 10.1016/j.bmcl.2022.128629. Epub 2022 Feb 16.